The global safety organization of Novartis is in the process of conducting a comprehensive review of a limited number of cases where patients treated with Beovu (brolucizumab) have experienced severe vision loss, inflammation, and potential retinal vasculitis.
The organization is postponing its annual meeting to July 2020 because of the developing COVID-19 outbreak.
FDA issued a notice to drug compounders regarding the transition of licensure of biologics to the Public Health Service Act.
A guidance document answers questions regarding the transition of biologics applications from under the FD&C Act to the PHS Act.
States, hospitals, and insurers support manufacturing arrangements to ensure access to affordable medicines.
Emergency action to protect patients and the drug supply may have long-term implications.
No matter why change may be needed, it is important to comply with all the relevant regulatory requirements, says Siegfried Schmitt, PhD, vice-president, technical, Parexel Consulting.
Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.
A study finds a potential risk of persistent visual side-effects in male patients taking the highest recommended dose of sildenafil.
While new industry guidance documents issued by FDA speak to the agency’s efforts to promote the development of new gene therapies, certain hurdles remain to challenge stakeholders.
Tackling process development early on can better optimize manufacturing processes for emerging therapies.
With the first announced drug shortage tied to the coronavirus outbreak, FDA emphasizes urgency for monitoring drug supply chain.
As the date for transitioning the approval of biologic drug to a new pathway comes closer, FDA publishes a final rule and answers questions on the pathway changes.
US and European regulatory officials continue to anticipate supply shortages in multiple areas.
An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.
FDA’s Center for Biologics Evaluation and Research is planning on publishing nine specific guidance documents on gene therapies in 2020.
The agency is taking steps to monitor the supply chain and assist in the development of treatments.
The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.
The report details OPQ’s accomplishments over the past five years.
The research community is moving quickly to launch clinical trials of potential countermeasures, while regulatory authorities aim to support product development through regulatory flexibility.
The two agencies are collaborating to support a robust biologics marketplace by taking steps to deter anti-competitive business practices.
FDA published draft guidance for applicants seeking licensure of a proposed biosimilar or proposed interchangeable biosimilar.
Can the pharmaceutical industry embrace the goals of Quality 4.0?
The FDA Commissioner plans to address drug prices, the drug approval process, and supply chain issues during his time as commissioner of FDA.
Increased reliance on foreign producers raises concerns and spurs collaborations.